uniQure Added to NASDAQ Biotechnology Index
December 11 2017 - 4:01PM
uniQure N.V. (NASDAQ:QURE), a leading gene therapy company
advancing transformative therapies for patients with severe medical
needs, today announced that the Company has been added to the
NASDAQ Biotechnology Index (NBI). The addition is part of NBI's
annual review of biotechnology and pharmaceutical companies listed
on the NASDAQ Stock Market that meet NBI's eligibility criteria.
uniQure will be added to the NBI effective prior to market open on
Monday, December 18, 2017.
The NASDAQ Biotechnology Index is a modified
market capitalization weighted index that is designed to track the
performance of a set of securities listed on The NASDAQ Stock
Market, that are classified as either biotechnology or
pharmaceutical according to the Industry Classification Benchmark
and is re-ranked annually in December. Additional information
on the eligibility criteria and further details about the index are
available through this link.
About uniQure uniQure is
delivering on the promise of gene therapy -- single treatments with
potentially curative results. We are leveraging our modular and
validated technology platform to rapidly advance a pipeline of
proprietary and partnered gene therapies to treat patients with
hemophilia, Huntington’s disease and cardiovascular diseases.
www.uniQure.com
uniQure Contacts:
Maria E. CantorDirect:
339-970-7536 Mobile:
617-680-9452m.cantor@uniqure.com
Eva M. Mulder Direct: +31 20 240
6103 Mobile: +31 6 52 33 15 79e.mulder@uniQure.com
Tom MaloneDirect:
339-970-7558Mobile: 339-223-8541t.malone@uniQure.com
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Mar 2024 to Apr 2024
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Apr 2023 to Apr 2024